Edit Target: 26
Akkermansia improves cancer immunotherapy.
Gram-negative anaerobic bacterium of the phylum Verrucomicrobia.
Akkermansia muciniphila is a typical member of the human gut microbiome.
Summary:
-Can significantly inhibit carcinogenesis and improve anti-tumor effects, thus increasing the effectiveness of cancer immunotherapy.
-Enhanced abundance of Akkermansia in the intestine of those who responded positively to the ICI(immune checkpoint inhibitors).
-Eat fermented foods then fibre to maintain them. Fruits and vegs for fibre Chicory root for fibre (inulin which is main prebiotic).
• Akkermansia muciniphila specializes in degrading mucin, the glycoprotein component of the mucus layer lining the gut.
• Early clinical findings suggest that higher levels of Akkermansia correlate with improved responses to immune checkpoint inhibitors in cancer therapy.(e.g., anti-PD-1/PD-L1 therapy).
Akkermansia, and in particular Akkermansia muciniphila, is a key gut bacterium implicated in supporting intestinal health, modulating immune responses, and influencing metabolic balance. Its roles in enhancing gut barrier integrity, reducing inflammation, and possibly improving responses to cancer immunotherapy make it an attractive target for probiotic development and microbiome-based interventions. Although not a drug in itself, Akkermansia’s potential as a biomarker and therapeutic adjunct offers promising avenues for integrative approaches in precision medicine and cancer care.